Loading clinical trials...
Loading clinical trials...
A Study Within a Trial to Determine the Effect of Skin Tone on the Diagnostic Accuracy of Pulse Oximeters
This study within a trial (SWAT) will be a sub-study of the UK-ROX trial (ISRCTN13384956), which is currently running in intensive care units across the UK. UK-ROX is large-scale randomised controlled trial evaluating conservative oxygen therapy (a target SpO2 of 88-92%) versus usual oxygen therapy in mechanically ventilated adult patients admitted to ICUs in the UK. The purpose of this observational sub-study is to compare pulse oximeter-derived peripheral oxygen saturation (SpO2) values to co-oximeter-derived arterial oxygen saturation (SaO2) measurements from arterial blood gas (ABG) samples, for a range of fingertip pulse oximeters in an ethnically diverse group of adult patients admitted to UK intensive care units (ICUs). Approximately 900 patients will be recruited over 12 month period from 24 sites to provide an anticipated 10,800 paired SpO2 and SaO2 measurements. Patient skin tone will be objectively measured using a handheld spectrophotometer. Data from the sub-study will be used to determine the accuracy of the tested pulse oximeters across a range of skin tones and arterial oxygenation levels.
Research question: What is the diagnostic accuracy of different pulse oximeters at peripheral oxygen saturation levels (SpO2) relevant to their use by patients at home and how does this vary in people with darker skin pigmentation? Primary objective: To compare pulse oximeter-derived SpO2 values to co-oximeter-derived arterial oxygen saturation (SaO2) measurements from arterial blood gas (ABG) samples, for a range of fingertip pulse oximeters in an ethnically diverse group of adult patients with a broad spectrum of skin tones admitted to UK intensive care units (ICUs). Design: This study within a trial (SWAT) that will form an observational sub-study of the NIHR HTA funded UK-ROX trial (https://fundingawards.nihr.ac.uk/award/NIHR130508), which is currently running in ICUs across the UK. Twenty four ICUs enrolling patients into the UK-ROX trial trial will be randomly allocated two brands of pulse oximeter to evaluate. Over a period of 24 hours for each participant, SpO2 values from the test pulse oximeters will be compared to simultaneous SaO2 values from ABG samples analysed on a standard ICU ABG co-oximeter machine. Patient skin tone will be objectively measured using a handheld spectrophotometer. The difference between SpO2 and SaO2 will be compared across skin tones and across a range of arterial oxygenation levels. Setting: The UK-ROX trial is large-scale, multi-centre, data-enabled, registry embedded randomised controlled trial (RCT) evaluating conservative oxygen therapy (a target SpO2 of 88-92%) versus usual oxygen therapy in mechanically ventilated adult patients admitted to ICUs in the United Kingdom. Target population: 900 mechanically ventilated adults screened for enrolment into the UK-ROX trial. Primary outcome: The accuracy of SpO2 measurement in the evaluated pulse oximeters, validated against co-oximeter-derived SaO2 ABG sample analysis.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Intensive Care National Audit and Research Centre
London, London, United Kingdom
Start Date
June 24, 2022
Primary Completion Date
August 15, 2024
Completion Date
October 31, 2024
Last Updated
March 12, 2025
903
ACTUAL participants
Pulse oximetry
DEVICE
Spectrophotometry
DEVICE
Lead Sponsor
Intensive Care National Audit & Research Centre
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07478380